New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease

Bibliography

• Rizzo M, Berneis K. Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention? J Atheroscler Thromb 2005;12:237-9
   PubMed Web of Science ®Google Scholar
• Tenenbaum A, Fisman EZ, Motro M, Adler Y. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovasc Diabetol 2006;5:20
   PubMed Web of Science ®Google Scholar
• Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003–2004. Am Heart J 2008;156(1):112-19
   Google Scholar
• Makadia SS, Blaha M, Keenan T, et al. Relation of hepatic steatosis to atherogenic dyslipidemia. Am J Cardiol 2013;112(10):1599-604
   Google Scholar
• Wilding JP. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes. Diabetes Obes Metab 2012;14:973-82
   PubMed Web of Science ®Google Scholar
• Kallwitz ER, McLachlan A, Cotler SJ. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J Gastroenterol 2008;14:22-8
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Role of ezetimibe in non-alcoholic fatty liver disease. World J Hepatol 2011;3:265-7
   PubMedGoogle Scholar
• Kostapanos MS, Kei A, Elisaf MS. Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. World J Hepatol 2013;5:470-8
   PubMedGoogle Scholar
• Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol 2011;9:698-705
   PubMed Web of Science ®Google Scholar
• Athyros VG, Tziomalos K, Gossios TD, et al.; GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376:1916-22
   PubMed Web of Science ®Google Scholar
• Bruckert E, Labreuche J, Deplanque D, et al. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. J Cardiovasc Pharmacol 2011;57:267-72
   PubMed Web of Science ®Google Scholar
• Lee M, Saver JL, Towfighi A, et al. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis 2011;217:492-8
   PubMed Web of Science ®Google Scholar
• Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370:1129-36
   PubMed Web of Science ®Google Scholar
• Erdmann E, Charbonnel B, Wilcox RG, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007;30:2773-8
   PubMed Web of Science ®Google Scholar
• Eurich DT, McAlister FA, Blackburn DF, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007;335:497
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005;366:1279-89
   PubMed Web of Science ®Google Scholar
• Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007;49:1772-80
   PubMed Web of Science ®Google Scholar
• Wilcox R, Bousser MG, Betteridge DJ, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007;38:865-73
   PubMed Web of Science ®Google Scholar
• Bardot O, Aldridge TC, Latruffe N, Green S. PPAR-RXR heterodimer activates a peroxisome proliferator response element upstream of the bifunctional enzyme gene. Biochem Biophys Res Commun 1993;192:37-45
   PubMed Web of Science ®Google Scholar
• Gearing KL, Gottlicher M, Teboul M, et al. Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc Natl Acad Sci USA 1993;90:1440-4
   PubMed Web of Science ®Google Scholar
• Wilding JP. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes. Diabetes Obes Metab 2012;14(11):973-82
   Google Scholar
• Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996;1302:93-109
   PubMed Web of Science ®Google Scholar
• Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996;37:907-25
   PubMed Web of Science ®Google Scholar
• Nagasawa T, Inada Y, Nakano S, et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 2006;536:182-91
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Watts GF. Fibrate therapy and circulating adiponectin concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Atherosclerosis 2013;230:110-20
   PubMed Web of Science ®Google Scholar
• Masaki T, Chiba S, Tatsukawa H, et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology 2004;40:177-84
   PubMed Web of Science ®Google Scholar
• Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008;77:289-312
   PubMed Web of Science ®Google Scholar
• Feige JN, Gelman L, Michalik L, et al. From molecular action to physiological outputs: peroxisome proliferator activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 2006;45:120-59
   PubMed Web of Science ®Google Scholar
• Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507-14
   PubMed Web of Science ®Google Scholar
• Van Wagner LB, Rinella ME. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Thera Adv Gastroenterol 2011;4:249-63
   PubMedGoogle Scholar
• Lutchman G, Promrat K, Kleiner DE, et al. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol 2006;4:1048-52
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003;38:1008-17
   PubMed Web of Science ®Google Scholar
• Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial. Gastroenterology 2008;135:100-10
   PubMed Web of Science ®Google Scholar
• Ratziu V, Charlotte F, Bernhardt C, et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010;51:445-53
   PubMed Web of Science ®Google Scholar
• Ratziu V, Caldwell S, Neuschwander-Tetri BA. Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues. Hepatology 2010;52:2206-15
   PubMed Web of Science ®Google Scholar
• Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-307
   PubMed Web of Science ®Google Scholar
• Tolman KG. The safety of thiazolidinediones. Expert Opin Drug Saf 2011;10:419-28
   PubMed Web of Science ®Google Scholar
• Rubenstrunk A, Hanf R, Hum DW, et al. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 2007;1771:1065-81
   PubMed Web of Science ®Google Scholar
• Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 2008;19:129-37
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-23
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54
   PubMed Web of Science ®Google Scholar
• Bojic LA, Huff MW. Peroxisome proliferator-activated receptor delta: amultifaceted metabolic player. Curr Opin Lipidol 2013;24:171-7
   PubMed Web of Science ®Google Scholar
• Gervois P, Fruchart JC, Staels B. Drug insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat Clin Pract Endocrinol Metab 2007;3:145-56
   PubMedGoogle Scholar
• Fruchart JC. Selective peroxisome proliferator-activated receptor alpha modulators (SPPARMalpha): the next generation of peroxisome proliferator-activated receptor alpha-agonists. Cardiovasc Diabetol 2013;12:82
   PubMed Web of Science ®Google Scholar
• Zhu T, Awni WM, Hosmane B, et al. ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans. J Clin Pharmacol 2009;49:63-71
   PubMed Web of Science ®Google Scholar
• Goldberg AC, Bays HE, Ballantyne CM, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol 2009;103:515-22
   PubMed Web of Science ®Google Scholar
• Mohiuddin SM, Pepine CJ, Kelly MT, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J 2009;157:195-203
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH, Kashyap ML, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis 2009;204:208-15
   PubMed Web of Science ®Google Scholar
• Takizawa T. K-877, a highly potent and selective PPAR alpha agonist, improves dyslipidemia and atherosclerosis in experimental animal models [abstract 787]. Avaialble from: http://www.kenes.com/eas2012/abstracts/pdf/787.pdf
   Google Scholar
• Ishibashi S, Arai H, Yamashita S, et al. Benefical effects of K-877, a potent and highly selective PPARalpha agonist, on plasma lipoprotein profile in patients with atherogenic dyslipidemia [abstract 525]. Proceedings of 80th EAS Congress; 26 – 29 May 2012; Milan, Italy
   Google Scholar
• Kendall DM, Rubin CJ, Mohideen P, et al. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study. Diabetes Care 2006;29:1016-23
   PubMed Web of Science ®Google Scholar
• Wilding JPH, Gause-Nilsson I, Persson A. Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes. Diab Vasc Dis Res 2007;4:194-203
   PubMedGoogle Scholar
• Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005;294:2581-6
   PubMed Web of Science ®Google Scholar
• AstraZeneca Discontinues Development of GALIDA (tesaglitazar). AstraZeneca. 2006-05-04. Retrieved 2013-11-11
   Google Scholar
• Sanwald-Ducray P, Liogier D'ardhuy X, Jamois C, Banken L. Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study. Clin Pharmacol Ther 2010;88:197-203
   PubMed Web of Science ®Google Scholar
• Henry RR, Lincoff AM, Mudaliar S, et al. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 2009;374:126-35
   PubMed Web of Science ®Google Scholar
• Sprecher DL, Massien C, Pearce G, et al. Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arterioscler Thromb Vasc Biol 2007;27:359-65
   PubMed Web of Science ®Google Scholar
• Risérus U, Sprecher D, Johnson T, et al. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 2008;57:332-9
   PubMed Web of Science ®Google Scholar
• Ooi EM, Watts GF, Sprecher DL, et al. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity. J Clin Endocrinol Metab 2011;96:E1568-76
   Web of Science ®Google Scholar
• Olson EJ, Pearce GL, Jones NP, Sprecher DL. Lipid effects of peroxisome proliferator-activated receptor-delta agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome. Arterioscler Thromb Vasc Biol 2012;32:2289-94
   PubMed Web of Science ®Google Scholar
• Bays HE, Schwartz S, Littlejohn T III, et al. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab 2011;96:2889-97
   PubMed Web of Science ®Google Scholar
• Choi YJ, Roberts BK, Wang X, et al. Effects of the PPAR-delta agonist MBX-8025 on atherogenic dyslipidemia. Atherosclerosis 2012;220:470-6
   PubMed Web of Science ®Google Scholar
• Hanf R, Darteil R, Hum DW, Staels B. GFT505 efficacy and safety in healthy volunteers and patients suffering from atherogenic dyslipidemia. Diabetologia [70th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 25-29, Orlando) 2010]. Diabetologia 2010;59(Suppl 1):abstract 677-P
   Google Scholar
• Cariou B, Zaïr Y, Staels B, Bruckert E. Effects of the new dual PPAR alpha/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 2011;34:2008-14
   PubMed Web of Science ®Google Scholar
• Cariou B, Hanf R, Lambert-Porcheron S, et al. Dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care 2013;36:2923-30
   PubMed Web of Science ®Google Scholar
• Staels B, Rubenstrunk A, Noel B, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 2013;58:1941-52
   PubMed Web of Science ®Google Scholar
• Whitehead JP. Diabetes: new conductors for the peroxisome proliferator-activated receptor gamma (PPARgamma) orchestra. Int J Biochem Cell Biol 2011;43:1071-4
   Web of Science ®Google Scholar
• Yew T, Toh SA, Millar JS. Selective peroxisome proliferator-activated receptor-gamma modulation to reduce cardiovascular risk in patients with insulin resistance. Recent Pat Cardiovasc Drug Discov 2012;7:33-41
   Google Scholar
• Dunn FL, Higgins LS, Fredrickson J, et al. INT131-004 study group. Selective modulation of PPARgamma activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with type 2 diabetes. J Diabetes Complications 2011;25:151-8
   PubMed Web of Science ®Google Scholar
• Naci H, Brugts JJ, Fleurence R, et al. Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials. Eur J Prev Cardiol 2013;20:641-57
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Sacks F, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008;102:1K-34K
   PubMed Web of Science ®Google Scholar
• Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-92
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 2013. [Epub ahead of print]
   Google Scholar
• Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-67
   PubMed Web of Science ®Google Scholar
• Merck. Merck announces HPS2-THRIVE study of Tredaptive™ (Extended-Release Niacin/Laropiprant) did not achieve primary endpoint [online]. Available from: http://www.mercknewsroom.com/press-release/prescription-medicine-news/merck-announces-hps2-thrive-study-tredaptive-extended-relea
   Google Scholar
• Watts GF, Karpe F. Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. Heart 2011;97:350-6
   PubMed Web of Science ®Google Scholar